Delivery of alprazolam, estazolam midazolam or triazolam through an inhalation route
First Claim
1. A method of treating anxiety or insomnia comprising administering a therapeutic amount of an alprazolam, estazolam, midazolam or triazolam condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% alprazolam, estazolam, midazolam or triazolam degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route. Specifically, it relates to aerosols containing alprazolam, estazolam, midazolam or triazolam that are used in inhalation therapy. In a method aspect of the present invention, alprazolam, estazolam, midazolam or triazolam is administered to a patient through an inhalation route. The method comprises: a) heating a composition of alprazolam, estazolam, midazolam or triazolam, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering alprazolam, estazolam, midazolam or triazolam through an inhalation route is provided which comprises: a) a thin coating of an alprazolam, estazolam, midazolam, or triazolam composition and b) a device for dispensing said thin coating as a condensation aerosol.
152 Citations
19 Claims
-
1. A method of treating anxiety or insomnia comprising administering a therapeutic amount of an alprazolam, estazolam, midazolam or triazolam condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% alprazolam, estazolam, midazolam or triazolam degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
10. A method of administering alprazolam, estazolam, midazolam, or triazolam to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of alprazolam, estazolam, midazolam, or triazolam having less than 5% alprazolam, estazolam, midazolam, or triazolam degradation products and an MMAD less than 3 microns wherein the peak plasma drug concentration is achieved in less than 0.1 hours.
-
11. A kit for delivering a drug aerosol comprising:
-
a) a thin coating of an alprazolam, estazolam, midazolam, or triazolam composition, and b) a device for dispensing said thin coating as a condensation aerosol. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19)
-
Specification